PASG

Passage BIO, Inc. (PASG) - Q2 2024 10-Q Summary

Business Context and Reporting Period

Passage BIO, Inc. is a clinical-stage genetic medicines company focused on developing one-time therapies for neurodegenerative diseases. The reporting period covers the quarter and six months ended June 30, 2024. The company's lead clinical candidate, PBFT02, targets frontotemporal dementia (FTD-GRN) and is currently in Phase 1/2 trials. The company is classified as a non-accelerated filer, smaller reporting company, and emerging growth company.

Key Financial Metrics

Material Changes vs. Prior Period

• Expense Reduction: Net loss decreased significantly by approximately 33% in Q2 and 44% in the six-month period compared to the prior year. This was driven by a strategic reduction in operating expenses.
• R&D Expenses: Decreased by $6.9 million in Q2 and $12.2 million in the six-month period. Drivers included reduced headcount, lower clinical operations costs for outlicensed programs (GM1, Krabbe), and reduced Penn collaboration expenses.
• G&A Expenses: Decreased by $1.6 million in Q2 and $14.1 million in the six-month period. The six-month decrease was largely due to the absence of a $11.3 million one-time charge related to the Amended Catalent Agreements recorded in the prior year.
• Impairment: The company recorded a $0.4 million impairment charge for long-lived assets (construction in progress) in Q2 2024, which was not present in the prior year.
• Financing Activity: In March 2024, the company raised $8.7 million in net proceeds via its At-The-Market (ATM) facility.

Guidance, Outlook, and Material Events

• Subsequent Event - Outlicense Transaction: On July 31, 2024, Passage BIO entered into agreements with Gemma Biotherapeutics, Inc. to outlicense three pediatric programs (GM1, Krabbe, MLD). The company expects to receive an initial $10 million payment for clinical product supply, up to $10 million in business milestones, and up to $114 million in development and commercial milestones, plus single-digit royalties.
• Liquidity Outlook: Management expects that existing cash, cash equivalents, marketable securities ($91.8 million), combined with initial payments from the Gemma transaction, will fund operations through the end of Q2 2026.
• Pipeline Updates:
  • PBFT02 (FTD-GRN): Cohort 1 dosing complete; Cohort 2 enrollment ongoing. Updated safety/biomarker data expected September 2024.
  • PBFT02 (FTD-C9orf72): Positive regulatory feedback received; dosing expected to initiate in H1 2025.
  • PBFT02 (ALS): Regulatory feedback expected in H2 2024.
• Risks: The company faces risks related to its reliance on third-party manufacturers (Catalent), the success of clinical trials, and the need for additional capital if the outlicense transaction does not fully offset future burn rates. The company is currently subject to litigation regarding a former employee's stock claim (mid-single digit millions).

Investor Verification Checklist

• Outlicense Closing: Verify the receipt of the initial $10 million payment from Gemma Biotherapeutics and the status of the transition services agreement.
• Cash Runway: Confirm the updated cash runway calculation post-outlicense transaction to ensure it supports the Q2 2026 projection.
• Catalent Relationship: Review the impact of the outlicense of GM1 on the Amended Catalent Agreements, specifically regarding potential divestiture fees or changes in exclusivity.
• Legal Proceedings: Monitor the status of the pending litigation with the former employee, including the anticipated trial date in Q4 2024.
• ATM Capacity: Note that $50 million of capacity remains available under the current ATM facility for future fundraising needs.